ArticleNeuro-oncology2022
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019.
Article in Neuro-oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 982 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Observational Study of Responses to Treatments in Advanced Central Nervous System (CNS) Tumors
Intratumoral DNX-2401 Administration for Recurrent and Refractory High Grade Brain Tumors in Pediatric and Young Adult Patients
Fluorescence-Guided Imaging of Brain Tumors: A Safety Study Using SBK2- ICG in a Phase 1 Clinical Trial
Who cites it
982 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Focused ultrasound-induced blood-brain barrier modulation for drug delivery in recurrent glioblastoma: A systematic review.The Indian journal of medical research · 2026Pooled it
- Postoperative outcomes in CNS WHO grade 2 and 3 meningioma: a systematic review and meta-analysis.Langenbeck's archives of surgery · 2026Pooled it
- Complications and outcomes after supracerebellar transtentorial approach for mediobasal temporal lobe intra-axial tumors: A systematic review and meta-analysis.Neurosurgical review · 2026Pooled it
- Bridging surgery and radiotherapy: the role of stereotactic radiosurgery in pediatric brain tumor care.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026Pooled it
- Efficacy and safety of tyrosine kinase inhibitor combination therapy for glioblastoma: a meta-analysis with trial sequential analysis of randomized controlled trials.Frontiers in oncology · 2026Pooled it
- A novel oncolytic herpes simplex virus type 2 induces polarization of tumor-associated macrophages and remodels the immune microenvironment in glioblastoma.Cancer immunology, immunotherapy : CII · 2026Trial
- Differentiation of high-grade glioma and primary central nervous system lymphoma based on imaging heterogeneity scoring system.Neurosurgical review · 2026Trial
- High levels of nitric oxide and peroxynitrite with protein nitration: a new therapeutic target for gliomas.Medical gas research · 2027Review
- Targeting USP14 sensitizes glioma to radiotherapy through exacerbated reactive oxygen species accumulation.Medical gas research · 2027Article
- MRI-based preoperative WHO grade prediction in meningioma: development and comparison of deep learning, radiomics, clinical, and combined models in multicenter data.Journal of neuro-oncology · 2026Article
- Supratentorial ependymoma: a comprehensive review of molecular classification, management strategies, and clinical outcomes (Part II of pediatric ependymomas across compartments).Journal of neuro-oncology · 2026Review
- Article
- Targeting LDHA Palmitoylation Sensitizes GBM to Chemoradiotherapy via Suppressing Palmitic Acid Induced Glycolytic Reprogramming.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Health-related quality of life and its determinants in patients with malignant brain tumors: a prospective longitudinal study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Staining collagen fibers in pituitary lesions substantially improves the certainty of intraoperative frozen section diagnosis.Pituitary · 2026Article
- Posterior fossa ependymoma: a comprehensive review of molecular classification, management guidelines, and clinical outcomes (Part I of ependymomas across compartments).Journal of neuro-oncology · 2026Review
- Gamma Knife radiosurgery delivered to internal auditory canal glioblastoma under a presumed diagnosis of vestibular schwannoma: illustrative case.Journal of neurosurgery. Case lessons · 2026Article
- Brain assembloids reveal efficacy and off target effects in high grade glioma brain cancer.iScience · 2026Article
- A comprehensive review on the current applications and future perspectives of radioembolization in endovascular neurosurgery.Journal of neurointerventional surgery · 2026Review
- Clinical Outcomes and New Treatments in Pediatric Brain Tumors.Current oncology (Toronto, Ont.) · 2026Article
922 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Central Brain Tumor Registry of the United States (CBTRUS), in collaboration with the Centers for Disease Control and Prevention and the National Cancer Institute, is the largest population-based registry focused exclusively on primary brain and other central nervous system (CNS) tumors in the United States (US) and represents the entire US population. This report contains the most up-to-date population-based data on primary brain tumors available and supersedes all previous reports in terms of completeness and accuracy. All rates are age-adjusted using the 2000 US standard population and presented per 100,000 population. The average annual age-adjusted incidence rate (AAAIR) of all malignant and non-malignant brain and other CNS tumors was 24.71 per 100,000 population (malignant AAAIR=7.02 and non-malignant AAAIR=17.69). This overall rate was higher in females compared to males (27.62 versus 21.60 per 100,000) and non-Hispanic persons compared to Hispanic persons (25.09 versus 22.95 per 100,000). The most commonly occurring malignant brain and other CNS histopathology was glioblastoma (14.2% of all tumors and 50.1% of all malignant tumors), and the most common non-malignant histopathology was meningioma (39.7% of all tumors and 55.4% of all non-malignant tumors). Glioblastoma was more common in males, and meningiomas were more common in females. In children and adolescents (ages 0-19 years), the incidence rate of all primary brain and other CNS tumors was 6.20 per 100,000 population. An estimated 93,470 new cases of malignant and non-malignant brain and other CNS tumors are expected to be diagnosed in the US population in 2022 (26,670 malignant and 66,806 non-malignant). There were 84,264 deaths attributed to malignant brain and other CNS tumors between 2015 and 2019. This represents an average annual mortality rate of 4.41 per 100,000 population and an average of 16,853 deaths per year. The five-year relative survival rate following diagnosis of a malignant brain and other CNS tumor was 35.7%, while for non-malignant brain and other CNS tumors the five-year relative survival rate was 91.8%.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.